A Phase 1, Multi-Center, Open-Label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics cf CC-94676 In Subjects with Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of
CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Inclusion Criteria:

- Must have histologically or cytologically confirmed adenocarcinoma of the prostate

- Progressed on androgen deprivation therapy (ADT) and at least one prior secondary
hormonal therapy approved for castration-resistant prostate cancer (CRPC)

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Exclusion Criteria:

- Prior treatment with an androgen receptor (AR) degrader

- Concurrent malignancy (present during screening) requiring treatment or history of
prior malignancy active within 1 year prior to the first dose of IP

- Clinically significant venous thromboembolism within 3 months prior to the first dose
of IP

- Any significant medical condition, such as uncontrolled infection, laboratory
abnormality, or psychiatric illness

Other protocol-defined inclusion/exclusion criteria apply